Algeta and Affibody Initiate Anticancer Targeted Therapy Collaboration

18-Aug-2006

Algeta ASA and Affibody AB announced a research collaboration agreement to develop novel targeted radiotherapeutics. The collaboration will combine Algeta's TH-1 technology for attaching the alpha-particle emitting radionuclide thorium-227 to peptides and proteins, with Affibody® molecules that specifically target tumor cells over-expressing HER2, such as those present in breast and other cancers.

Targeted radiotherapeutics based on these leading-edge technologies will benefit from the proven high specificity and affinity of Affibody® molecules for their targets, which rivals, according to the company, that of antibodies but with significant physical and production advantages, and the high-energy, short-range alpha particle radiation from thorium-227. When thorium-227-labelled radiotherapeutics attach to tumor cells via unique molecular binding sites, a lethal dose of alpha-particle radiation destroys multiple tumor cells within a limited 2-10 cell diameter range of the binding site while leaving non-tumor tissue largely unaffected.

Clinical data confirm that Affibody® molecules can be engineered to have high tumor specificity. High affinity Affibody® molecules have been developed against a number of relevant therapy target proteins. These molecules will be used as carriers for different types of toxins in tumor therapy. Application of Affibody's proprietary albumin-binding technology yields Affibody® fusion proteins with biodistribution properties that perfectly match the half-life of thorium-227 (t1/2 = 18.7 days).

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous